Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ebola Threat Prompts EU To Focus On Adaptive Licensing

This article was originally published in The Pink Sheet Daily

Executive Summary

The spread of Ebola to Europe is prompting regulators and industry to explore in more detail adaptive licensing pathways to speed access to potentially life-saving drugs.

You may also be interested in...



U.K.’s NICE Plans Office To Help Drugs Gain Coverage Faster

NICE is responding to a government consultation on how the cost-effectiveness watchdog should update its methodologies and processes in evaluating new products by opening a new Office for Market Access, which it says will help life sciences companies prepare for its appraisals and better their chances for coverage.

European Notebook: Piloting Adaptive Pathways; Hepatitis C Pricing; IPO Window

The first six medicines are selected to pilot Europe’s speedier patient access scheme; France’s proposed health care reforms attract opposition, including a doctors' strike; European biotech companies expect a continuing funding stream from IPOs over the next 12 months.

Europe Mustering Its Scientific And Political Arsenal At Ebola And Beyond

The European Union and the EU drug industry have targeted over €1.25 billion for fighting Ebola, through research projects for vaccines, diagnostics and therapies, and direct aid to West Africa.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS076516

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel